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Abstract: Phenoxybenzamine (PBZ) is an FDA approved α-1 adrenergic receptor 
antagonist that is currently used to treat symptoms of pheochromocytoma. However, it has 
not been studied as a neuroprotective agent for traumatic brain injury (TBI). While 
screening neuroprotective candidates, we found that phenoxybenzamine reduced neuronal 
death in rat hippocampal slice cultures following exposure to oxygen glucose deprivation 
(OGD). Using this system, we found that phenoxybenzamine reduced neuronal death over 
a broad dose range (0.1 µM–1 mM) and provided efficacy when delivered up to 16 h  
post-OGD. We further tested phenoxybenzamine in the rat lateral fluid percussion model 
of TBI. When administered 8 h after TBI, phenoxybenzamine improved neurological 
severity scoring and foot fault assessments. At 25 days post injury, phenoxybenzamine 
treated TBI animals also showed a significant improvement in both learning and memory 
compared to saline treated controls. We further examined gene expression changes within 
the cortex following TBI. At 32 h post-TBI phenoxybenzamine treated animals had 
significantly lower expression of pro-inflammatory signaling proteins CCL2, IL1β, and 
MyD88, suggesting that phenoxybenzamine may exert a neuroprotective effect by reducing 
neuroinflammation after TBI. These data suggest that phenonxybenzamine may have 
application in the treatment of TBI.  
Keywords: phenoxybenzamine; traumatic brain injury; neuroprotection; morris  
water maze 
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1. Introduction 
Traumatic brain injury (TBI) is a national health concern that affects over 1.7 million individuals 
each year in the United States [1–3]. Of further concern is the lack of effective treatments to reduce  
the primary or secondary phase of neuropathology induced by TBI. The development of novel 
neuroprotective agents has proven difficult as TBI represents a heterologous injury [4–9]. In an effort 
to discover new treatments for TBI, we have used a rat organotypic, hippocampal slice culture model 
of oxygen glucose deprivation (OGD) as an initial screen to identify potential neuroprotective 
candidate compounds [10]. While it is clear there are differences between stroke and TBI, there are 
similarities in the mechanisms that lead to neuropathology. Both injuries induce the development of 
inflammation, reactive oxygen species (ROS), reactive nitrogen species (RNS), excitotoxicity, calcium 
dysregulation, and apoptosis [5,8–12]. TBI also results in sheared blood vessels leading to impaired 
blood flow and ischemia [11–13]. Thus, utilizing an in vitro model of OGD to screen for potential 
neuroprotective compounds represents an efficient method to identify potential neuroprotective 
compounds. We previously used this approach to identify low dose methamphetamine as a potential 
neuroprotective candidate, which was highly effective when tested in the rat lateral fluid percussion 
(LFP) injury model of severe TBI [10].  
Using the rat hippocampal slice culture model, we have recently made the novel observation  
that phenoxybenzamine exerts a profound neuroprotective effect following OGD. Currently, 
phenoxybenzamine is an FDA approved treatment for humans and animals to reduce hypertension and 
excessive sweating associated with adrenal tumors (pheochromocytoma) [14–16]. Pharmacologically, 
phenoxybenzamine (Dibenzyline; Wellspring Pharmaceuticals) is a halo-alkylamine that blocks both α-1 
and α-2 adrenergic receptors, but has a higher affinity for the α-1 receptor [16,17]. Following i.v. 
administration, receptor antagonism achieves a peak effect at approximately 1 h [17]. However, 
phenoxybenzamine exerts a long-term effect in the brain with a half-life of approximately 24 hours. As 
an antagonist, phenoxybenzamine forms an irreversible covalent bond with α-adrenergic receptors, 
thus the effect of the drug lasts longer than its metabolic half-life [17]. This observation is supported 
by studies showing the reversal of the effect of phenoxybenzamine is dependent on the synthesis of 
new receptors and not metabolism of the drug. Hamilton et al. demonstrated that only 50% of α-1 
receptors had recovered eight days after a single administration of phenoxybenzamine [17]. Based on 
prior FDA approval of phenoxybenzamine, its stability and ease of administration, relatively long 
effect, and the absence of harmful side effects; we elected to further investigate phenoxybenzamine as 
a potential neuroprotective agent in the treatment of TBI. 
As a proof-of-concept study, we utilized the rat LFP injury model to test the neuroprotective 
potential of phenoxybenzamine [18]. Importantly, we chose the clinically relevant time point of 8 h 
after injury to test the potential neuroprotective effect. The administration of a single, i.v., bolus dose 
of 1.0 mg/kg at 8 h after injury resulted in significant, long-term behavioral and cognitive 
improvements. To investigate the possible mechanisms of phenoxybenzamine-mediated neuroprotection 
we performed a gene array analysis and identified relevant gene targets that were altered as a result of 
phenoxybenzamine treatment and then confirmed the changes in gene expression by quantitative  
real-time PCR. 
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2. Results and Discussion 
2.1. Phenoxybenzamine Prevents Hippocampal Cell Death after Oxygen Glucose Deprivation 
Our preliminary studies in the rat hippocampal slice culture (RHSC)-OGD model identified 
phenoxybenzamine as a potential neuroprotective candidate compound. We further tested 
phenoxybenzamine in the RHSC-OGD model by conducting a dose response study. 
Phenoxybenzamine preserved primary neurons within the CA1, CA3 and dentate gyrus and produced a 
robust neuroprotective effect over a broad dose range (0.1 µM–1 mM final media concentration) 
(Figure 1a). Neuroprotective compounds must be effective when administered at a clinically relevant 
time point, which in the case of stroke or traumatic brain injury can be hours after injury. Therefore, 
we examined the potential therapeutic window of phenoxybenzamine in the RHSC-OGD model.  
A middle dose (100 µM) was selected and added to the cultures at 2, 4, 8, or 16 h post-OGD. We 
found that phenoxybenzamine prevented neuronal death from OGD in all regions of the hippocampus 
when delivered at 2, 4, and 8 h post-OGD. When delivered at 16 h post-OGD, phenoxybenzamine 
prevented neuronal death only in the CA1 region of the hippocampus (Figure 2a). Taken together, 
these data demonstrated a neuroprotective role for phenoxybenzamine under OGD conditions.  
Figure 1. (a) Phenoxybenzamine, over a broad dose range, provides significant 
neuroprotection from oxygen glucose deprivation in rat hippocampal slices cultures. Rat 
hippocampal slice cultures were exposed to 60 min of oxygen glucose deprivation (OGD). 
Immediately after OGD slices were treated with varying doses of phenoxybenzamine. Then 
21 h after OGD the slices were stained with propidium iodide and then visualized at 24 h. 
PBZ treatment from 0.1 µM–1 mM significantly reduced neuronal death from OGD in the 
CA1, CA3, and DG region of the hippocampus. *** p < 0.001, n = a minimum of seven 
slices; (b) non-OGD control; (c) OGD+phenoxybenzamine treated at 0.1 µM; (d) OGD + 
phenoxybenzamine treated at 10 µM; (e) OGD + phenoxybenzamine treated at 100 µM;  
(f) OGD + phenoxybenzamine treated at 1 mM; (g) OGD untreated control.  
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Figure 2. (a) Phenoxybenzamine (PBZ), delivered up to 16 h post injury, provides 
significant neuroprotection from oxygen glucose deprivation in rat hippocampal slice 
cultures. Rat hippocampal slice cultures were exposed to 60 min of OGD. At various time 
points after OGD, 100 µM PBZ was added to cultures. 21 h after OGD the slices were 
stained with propidium iodide and then visualized at 24 h. PBZ treatment at 100 µM 
significantly reduced neuronal death in the CA1, CA3, and DG region of the hippocampus 
when delivered at 2, 4, and 8 h post-OGD. Delivery of 100 µM PBZ at 16 h post-OGD 
significantly reduced neuronal death from OGD in the CA1 region of the hippocampus but 
did not reduce cell death in the CA3 or DG. *** p < 0.001, n = a minimum of seven slices; 
(b) non-OGD control; (c) OGD + phenoxybenzamine treated at 2 h post-OGD;  
(d) OGD + phenoxybenzamine treated at 4 h post-OGD; (e) OGD + phenoxybenzamine 
treated at 8 h post-OGD; (f) OGD + phenoxybenzamine treated at 16 h post-OGD;  
(g) OGD untreated control.  
 
2.2. Phenoxybenzamine Prevents Neurological Dysfunction that Occurs as a Result of Severe TBI  
To test the effect of phenoxybenzamine in TBI, we utilized the rat lateral fluid percussion (LFP) 
injury model. The LFP model is one of the most widely used models of closed head injury and 
reproduces many of the conditions observed in humans following TBI [19]. In this model, a fluid pulse 
delivered to the intact dura produces a rotational torque and coup/contre coup typically observed with 
closed head injury [20,21]. In choosing our test dose, we extrapolated a relevant rat dose based on 
current FDA approved levels. In humans, phenoxybenzamine can be administered daily at doses up to 
120 mg total [14,16,17,22]. Based on an average human weight of 70 kg, this represents 1.7 mg/kg. 
Therefore, we selected a slightly lower, single, i.v. dose of 1 mg/kg. This dose was then administered 
at the clinically relevant time point of 8 h after severe TBI. Therapeutic effectiveness was determined 
based on behavioral and cognitive outcomes.  
Neurological severity score (NSS) and foot fault assessments were used to test the hypothesis that 
phenoxybenzamine treatment could improve behavioral outcomes. Animals were assessed 24 h after 
injury and on 7, 14, 21, and 30 days post-TBI. We found no significant differences in NSS or foot fault 
scoring between the saline treated controls and phenoxybenzamine treated animals at 24 h or 7 days 
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after the TBI. These data confirm that all animals in both treatment groups experienced injuries of 
similar severity. However, phenoxybenzamine treated animals showed significant improvements in 
NSS and foot fault scoring on days 14, 21, and 30 (Figure 3a,b). It is worth noting that 
phenoxybenzamine treated rats had foot fault values that were not significantly different from 
uninjured control rats on days 21 and 30 of testing. 
Figure 3. (a) Phenoxybenzamine, delivered 8 h after a severe traumatic brain injury (TBI) 
significantly reduced neurological impairment. PBZ at 1.0 mg/kg was delivered 8 h after a 
severe TBI. At 24 h and 7 days post-injury there was no significant difference in 
neurological impairment. Beginning on day 14 post-injury, significant differences in 
neurological severity scores were observed. This trend continued on day 21 and day 30 
post-injury with significant differences observed between PBZ treated injured animals and 
saline treated injured animals. * p < 0.05, *** p < 0.001, n = a minimum of nine animals. 
(b) Phenoxybenzamine, delivered 8 hours after a severe TBI, significantly reduced foot 
fault errors. PBZ at 1.0 mg/kg was delivered 8 h after a severe TBI. At 24 h and 7 days 
post-injury there was no significant difference in foot fault errors. Beginning on day 14 
post-injury, significant differences in foot fault errors was observed. This trend continued 
on day 21 and day 30 post-injury with significant differences observed between PBZ 
treated injured animals and saline treated injured animals. ** p < 0.01, n = 13 for saline 
treated TBI; n = 9 for phenoxybenzamine treated TBI animals; n = 8 for surgical shams. 
 
(a) (b) 
2.3. Phenoxybenzamine Reduces Cognitive Impairment Associated with Severe TBI  
The Morris water maze (MWM) was used to assess cognitive function of rats beginning 25 days 
after injury. A single, i.v., administration of phenoxybenzamine at 8 h after TBI resulted in significant 
learning improvement on days 2–5 of the training phase (Figure 4a). Phenoxybenzamine treated 
animals were not significantly different from the un-injured, sham operated control animals on any of 
the training days. After the learning phase was completed, a probe trial was conducted to assess spatial 
memory function. During the probe trial the phenoxybenzamine treated animals displayed significantly 
greater spatial memory capacity compared to the saline treated controls (Figure 3b). The 
phenoxybenzamine treated TBI animals spent approximately 28% of available time searching the 
target quadrant for the removed escape platform. In contrast, saline treated controls spent 
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approximately 10% of available time searching the target quadrant. As in the training phase, the 
phenoxybenzamine treated TBI injured animals did not differ from un-injured sham controls, which 
spent approximately 25% of their time searching the target quadrant (Figure 4b).  
Figure 4. (a) Phenoxybenzamine, delivered 8 h after a severe TBI, significantly reduced 
learning impairment. Phenoxybenzamine at 1.0 mg/kg was delivered 8 hours after a severe 
TBI. Beginning 25 days post-TBI the animals were acclimated and trained in the Morris 
Water Maze. Animals were given four trials per day for two minutes per trial. Animals that 
failed to find the platform after two minutes were placed on the platform for 30 s to 
observe the visual cues. Beginning on day two of the training, the PBZ treated injured 
animals were significantly different from saline treated injured animals. This trend 
continued for the remainder of the training phase with significant differences between PBZ 
and saline treated animals present on days 2, 3, 4, and 5 of the training. For all five training 
days there were no significant differences between the un-injured shams and the PBZ 
treated animals. There was no significant difference in swim speeds for any of the animals 
in this study. * p < 0.05; ** p < 0.01; *** p < 0.001, n = 9 for saline treated TBI; n = 8 for 
phenoxybenzamine treated TBI animals; n = 8 for surgical shams. (b) Phenoxybenzamine, 
delivered 8 h after a severe TBI, significantly reduced memory impairment. 
Phenoxybenzamine at 1.0 mg/kg was delivered 8 h after a severe TBI. After the learning 
phase was completed, a probe trial was conducted to assess spatial memory function. The 
escape platform was removed and the animals were allowed to swim freely for 60 s. The 
amount of time spent searching in the target (platform) quadrant was recorded. During the 
probe trial the phenoxybenzamine treated animals displayed significantly greater spatial 
memory capacity when compared to the saline treated controls. The phenoxybenzamine 
treated TBI animals spent approximately 28% of available time searching the target 
quadrant for the escape platform compared to the 10% observed in saline treated TBI 
animals. As in the training phase, the phenoxybenzamine treated TBI injured animals did 
not differ from un-injured sham controls, which spent approximately 25% of their time 
searching the target quadrant. There was no significant difference in swim speeds for any 
of the animals in this study. ** p < 0.01, n = 9 for saline treated TBI; n = 8 for 
phenoxybenzamine treated TBI animals; n = 8 for surgical shams.  
 
(a) (b) 
  
1 2 3 4 5 6
0
50
100
150
 Phenoxybenzamine
 Saline
***
***
 Shams
**
Days of Training
S
ec
on
ds
 (
m
ea
n±
S
E
M
)
0
10
20
30
40
****
TBI Injured
Saline treated
TBI Injured
PBX 
treated
Surgical
Shams
%
 o
f 
tim
e 
in
 ta
rg
et
 q
au
dr
an
t (
+
/- 
S
E
M
)
Int. J. Mol. Sci. 2014, 15 1408 
 
 
2.4. Phenoxybenzamine Reduces the Expression of Pro-Inflammatory Genes 
In an effort to elucidate the possible mechanisms involved in phenoxybenzamine-mediated 
neuroprotection, we performed a gene array analysis of cortical tissue taken from animals at 32 h after 
the injury (8 h delay to treatment + 24 h after treatment). This time point was chosen in an effort to 
detect possible gene changes that would affect the development of secondary damage. The gene array 
screened for expression change in 24,0000 genes. From this initial screen, we identified a subset of  
12 genes that appeared to exhibit significant changes and were potentially relevant to mechanisms of 
neuroprotection (Table 1). We further examined this subset of genes by quantitative rtPCR. 
Importantly, we detected a significant increase in the expression of the pro-inflammatory signaling 
proteins CCL2 (11 fold, p = 0.004), IL1β (4.6 fold, p = 0.005) and MyD88 (3 fold, p = 0.0001) 
following severe TBI (Table 1). In contrast, rats treated with phenoxybenzamine after severe TBI 
showed no significant increase in the expression of these proinflammatory genes. These data suggest 
that phenoxybenzamine may mediate neuroprotection by modulating the neuroinflammatory response. 
TBI also induced significant changes in cellular retinol binding protein 2 (Rbp2) and corticotrophin 
releasing hormone (CRH). However, similar changes to the expression of these genes were seen in 
both saline and methamphetamine treated groups. Finally, TBI induced a slight but statistically 
significant increase in the expression of the calcium permeable AMPA receptor (GRIA4). In contrast, 
methamphetamine treatment resulted in no significant increase in GRIA4 expression.  
Table 1. Gene Expression Analysis. 
Genes 
Saline Phenoxybenzamine 
Fold Change p-value Fold Change p-value 
CCL2 11.12 0.004 3.34 0.92 
CXCL12 1.58 0.04 1.02 0.55 
Fos 1.46 0.23 −1.64 0.08 
IL1β 4.58 0.005 1.53 0.71 
Gadd45g 2.22 0.69 1.02 0.16 
Myd88 3.03 0.0001 1.27 0.20 
Pdgfα 1.21 0.10 −1.28 0.09 
NTS 1.12 0.60 1.23 0.19 
Rbp2 3.96 0.00008 1.58 0.03 
CRH −1.66 0.002 −1.56 0.003 
GRIA4 1.47 0.005 −1.14 0.50 
GRIA2 1.11 0.42 −1.17 0.19 
2.5. Discussion 
We have demonstrated that a single i.v. administration of 1.0 mg/kg of phenoxybenzamine, 
delivered 8 h after TBI, significantly reduced both behavioral and cognitive impairment. This 
represents a novel finding as there are no previous studies indicating that phenoxybenzamine exerts 
any type neuroprotective effects. Currently, phenoxybenzamine is used to treat hypertension and 
excessive sweating associated with adrenal tumors (pheochromocytoma). Interestingly, 
phenoxybenzamine does not appear to decrease global cerebral blood flow [23]. It does, however, 
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appear to re-distribute flow among certain regions of the brain [23]. Buchweitz and Weiss [23] 
performed studies in which they found phenoxybenzamine reduced blood flow in certain cortical 
regions and the hippocampus, but increased blood flow in the pons and substantia nigra. 
Mechanistically, phenoxybenzamine acts as a potent α-1 adrenergic antagonist (with secondary α-2 
antagonism) and thus blocks the effects of epinephrine and norepinephrine [16,24]. There is evidence 
that suggests blocking the effects of epinephrine and norepinephrine may provide significant benefits 
to TBI patients. Severe TBI increases the activity of the sympathetic nervous system resulting in the 
excessive release of epinephrine and norepinephrine [25]. Previous research indicates a direct 
correlation between the severity of TBI, plasma epinephrine and norepinephrine levels, and recovery 
rates [25]. Patients remaining in a persistent coma have epinephrine and norepinephrine plasma levels 
several-fold higher than controls. Furthermore, these catecholamine levels remain elevated for the 
duration of the comatose state. Conversely, TBI patients with initial catecholamine levels that are 
mildly elevated have been found to consistently improve to a Glasgow Comma Scale (GCS) value 
greater than 11 at one week post-TBI. In patients with multisystem trauma and TBI, plasma 
norepinephrine levels at 48 h post injury were predictive of the GCS at one week [26,27]. Plasma 
norepinephrine also correlated with patient survival, the number of ventilator days, and the length of 
hospital stay [24,26,27].  
In terms of cognitive function, the increased presence of norepinephrine in TBI has been associated 
with poor neuropsychological outcome. Kobori et al. [28], found that the administration of the α-1 
antagonist Prazosin, at 14 days after a TBI, significantly improved working memory in rats [28]. 
Kobori et al. [28] went on to elucidate a proposed mechanism that linked the impaired working 
memory with TBI mediated increase in the presence of α-1 in the medial pre-frontal cortex. The 
increased α-1 was linked to a CREB mediated increase in α-1 receptor gene transcription through 
binding of phospho-CREB to CRE sites on the α-1A receptor suggesting a positive feedback effect.  
Based on these studies, the neuroprotective effect of phenoxybenzamine may be a direct result of 
the α-1 and α-2 antagonism that blocks the secondary effects of norepinephrine signaling in the brain. 
The alpha 1 adrenergic receptor is coupled to a heterotrimeric G protein, Gq, which activates 
phospholipase C (PLC) [29]. PLC produces an increase in IP3 and calcium, which, in turn, activates 
protein kinase C (PKC) [30,31]. Previous studies in TBI have demonstrated that PKC is rapidly 
elevated as a result of the injury [30]. Another potential mechanism of neuroprotection associated with 
phenoxybenamine may be a reduction in calmodulin(CaM)/CaMKII activity. Phenoxybenzamine is 
also a potent inhibitor of CaM/CaMKII activity [29]. Under basal conditions CaMKII is a major 
mediator of glutamate signaling, however, under acute injury conditions, CaM/CaMKII interacts with 
the NR2B subunit of NMDA receptors leading to excitotoxic death [32]. There is evidence that 
CaM/CaMKII increases the trafficking of AMPA receptors to the cell surface leading to greater 
excitotoxic death during acute injury [32]. Supporting a neurodestructive role for CaMKII,  
Zhang et al. [33] found that TBI increased the expression of CaMKIIδ. Pre-treating rats with a 
CaMKIIδ inhibitor before TBI resulted in a significant decrease in lesion volume and a significant 
increase in neuromotor function [33]. Zhang et al. [33] went on to elucidate a mechanism in which 
CaMKIIδ actively promotes apoptosis in neurons by increasing the pro-apoptotic protein BAX and 
subsequent caspase 3 activation [33].  
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From gene array studies we found that phenoxybenzamine appears to block critical gene changes 
that occur after TBI. Genes involved in inflammation such as CCl2, IL-1β, and MyD88 were all 
significantly elevated in TBI animals, but phenoxybenzamine treated animals did not differ from 
uninjured control rats. This is a crucial finding because inflammation contributes to the formation of 
edema, a loss of neurons, and negatively affects patient recovery. A key component of brain 
inflammation is the recruitment of neutrophils and monocytes, which are toxic to neurons [34–38]. 
Recruitment of monocytes into the brain is primarily controlled by monocyte chemotactic protein 1 
(MCP-1) also known as CCL2, which is expressed by astrocytes, macrophages, and reactive  
microglia [36,39]. After TBI, CCL2 actively recruits monocytes to areas of brain damage leading to 
inflammation, edema and neuronal damage [39]. Rhodes et al. [40], found a rapid increase in CCL2 in 
human spinal fluid following severe TBI. Furthermore, CCL2 levels remained significantly elevated 
for up to 10 days post-injury [34]. Semple et al. [34] reported that elevated levels of CCL2 were 
detected in the serum of patients who died after TBI. 
Epithelial cells actively synthesize CCL2 in response to the proinflammatory cytokine,  
interleukin-1β (IL-1β) [41,42]. From our gene array analysis, we found that saline treated animals had 
a significant increase in IL-1β after TBI whereas phenoxybenzamine treated animals showed no 
significant increase. In terms of TBI, IL-1β is the primary activator of microglia and is directly 
responsible for inducing inflammation [6,8,43]. IL-1β further contributes to immunoexcitoxicty by 
enhancing the sensitivity of NMDA receptors and tumor necrosis factor alpha (TNF-α) leading to 
increased brain inflammation and excitotoxicity [8,44–46].  
Phenoxybenzamine may further reduce post-traumatic inflammation by reducing expression of 
myeloid differentiation primary response protein 88 (Myd88). Myd88 is a key adaptor protein involved 
in Toll-like receptor and pro-inflammatory cytokine signal transduction [47,48]. In saline treated TBI 
animals, Myd88 was significantly up-regulated over uninjured controls. However, MyD88 expression 
levels were equivalent to uninjured controls in phenoxybenzamine treated rats after TBI. 
Mechanistically, Myd88 is a key adaptor protein for Toll-like receptors, cytokines, and nuclear factor 
kappaB (NF-κB) [47,48]. Previous research suggests activation of Toll-like receptors results in the 
recruitment of Myd88 and the subsequent activation of NF-κB, which in turn, induces the rapid 
expression of pro-inflammatory molecules including tumor necrosis factor a (TNF-α), IL-1β, 
interleukin-6 (IL-6), and intracellular adhesion molecule-1 (ICAM-1) leading to a pro-inflammatory 
response [47–50]. These data strongly suggest that phenoxybenzamine is a valid candidate for further 
investigation as a potential neuroprotective agent and treatment for TBI. 
3. Experimental Section  
3.1. Rat Organotypic Hippocampal Slice Cultures  
All experimental animal procedures were approved by the University of Montana Institutional 
Animal Care and Use Committee in accordance with National Institutes of Health guide for the care 
and use of Laboratory animals (NIH Publications No. 8023). Hippocampal slice cultures were prepared 
from the brains of 7-day-old Sprague-Dawley rat pups as previously described [51]. After 7 days in 
culture, slices were exposed to oxygen-glucose deprivation. A glucose free balanced salt solution 
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(BSS) composed of 120 mM NaCl (EMD Science, Gibbstown, NJ, USA), 5 mM KCl (Sigma Aldrich, 
St. Louis, MO, USA), 1.25 mM NaH2PO4 (EMD Science, Gibbstown, NJ, USA), 2 mM MgSO4  
(Sigma Aldrich, St. Louis, MO, USA), 2 mM CaCl2 (Sigma Aldrich, St. Louis, MO, USA),  
25 mM NaHCO3 (Sigma Aldrich, St. Louis, MO, USA), 20 mM HEPES (EMD Science, Gibbstown, 
NJ, USA), 25 mM sucrose (Sigma Aldrich, St. Louis, MO, USA); pH 7.3 was bubbled for 1 h with 5% 
CO2/95% N2 at 10 L/h. Slices were washed 6 times in deoxygenated SBSS to remove residual glucose, 
transferred into deoxygenated SBSS and placed in a 37 °C chamber with a ProOx 110 oxygen 
feedback sensor (BioSpherix, Lacona, NY, USA) that maintained gas levels at 0.1% O2, 5% CO2, 
94.4% Nitrogen for 60 min. After OGD, the slices were immediately transferred back into pre-warmed 
Neurobasal media containing B27 without anti-oxidants (Life technologies Carlsbad, CA, USA) under 
normal oxygen conditions. Slices treated with phenoxybenzamine (Sigma Aldrich, St. Louis, MO, 
USA) in the dose-response study were placed in pre-warmed Neurobasal media containing  
0.1 μM–1 mM phenoxybenzamine immediately after OGD. For the time course studies, 100 μM 
phenoxybenzamine was added to Neurobasal media at 2, 4, 8, or 16 h after OGD. Neuronal damage 
was determined by staining slices with propidium iodide (PI) (Molecular Probes, Eugene, OR, USA) 
and quantifying the relative fluorescence intensity (excitation 540/emission 630) using ImagePro Plus 
software (Media Cybernetics, Silver Springs, MD, USA). PI was added to the media at a concentration 
of 2 μM [52], 4 h prior to OGD. Images were taken of the hippocampal slices prior to OGD to 
establish baseline fluorescence. After OGD, slices were placed in normal media containing 2 μM PI 
and imaged again at 24 h post-OGD using fluorescence optics with an Olympus IMT-2 microscope 
and a Hamamatsu camera. The total fluorescent intensity in each slice was determined using  
ImagePro Plus software (Media Cybernetics, Silver Springs, MD, USA) and all values were expressed 
as an integrated optical density (IOD) which calculates the area multiplied by the pixel number and 
intensity to give a total fluorescent staining intensity that measures the amount of cell death.  
3.2. TBI Procedure  
Male Wistar rats (350–500 g) were obtained from Charles River Laboratories (Wilmington, MA, 
USA) and housed with a 12-h light/dark cycle and ad libitum access to food and water. Severe TBI 
was induced using the LFP procedure as previously described [18]. Briefly, a 5 mm craniotomy was 
made over the right hemisphere equidistant between the lambda and the bregma. Animals were given a 
fluid pulse to the brain at 1.9–2.3 ATM of pressure with a 20 ms duration using an FP 302 LFP 
machine (AmScien Instruments, Richmond, VA, USA). All animals experienced apnea and were 
manually ventilated on 0.5 liters O2/min until normal breathing occurred. Throughout the procedure 
and for 3 h post-injury, body temperature, heart rate, and spO2 levels were monitored and recorded. 
Animals had an average righting time of 24 min and an average mortality rate of 25% was observed. 
Mild to moderate TBI injuries (NSS < 9) that were excluded from the study was 14%. At 8 h post-TBI, 
phenoxybenzamine hydrochloride (Sigma Aldrich, St. Louis, MO, USA) at 1 mg/kg dissolved into  
200 µL of sterile saline was injected into the tail vein of randomly selected rats using a 25-gauge 
needle. Saline treated animals underwent the same tail vein injection procedure but received 200 µL of 
saline. Sham operated animals received a craniotomy but did not receive a TBI. Post surgery, the 
animals were monitored twice daily for one week. Each day of the first week following TBI, all 
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animals were given 10 mL pre-warmed supplemental saline given subcutaneously, and 100 g of AD 
Veterinary diet (to stimulate eating and minimize weight loss). All animals were weighed once daily 
for two weeks post TBI.  
3.3. Neurological Severity Scoring  
Neurological severity scoring (NSS) and foot fault assessments were performed as previously 
described [10,18]. Assessements were conducted on days 1, 7, 14, 21, and 30 by a blinded observer. 
Scores ranged from 0–16 with 16 indicating maximal impairment. Scoring criteria for a severe TBI 
was an NSS in the range of 10–16. Animals scoring an NSS of 9 or less on day 1 post injury were 
identified as having a moderate/mild injury and were excluded. Animals that scored 10 or greater on 
their NSS were randomly distributed into saline or phenoxybenzamine treated groups. For this study 
13 animals were placed in the saline group with a mean day 1 NSS of 12.7 and nine animals were 
placed in the phenoxybenzamine group with a mean day 1 NSS of 12.0.  
3.4. Foot Faults Assessments 
Foot fault assessments were conducted as previously described [10,18]. Briefly, rats were set on an 
elevated grid. With each weight-bearing step, the paw may fall or slip off the wire grid. Each time the 
left forelimb (affected by damage to the right hemisphere) missed a placement on the wire rack it was 
recorded as a foot fault. The total number of steps that the rat used to cross the grid was counted, and 
the total numbers of foot faults for the left forelimb was recorded. The total number of left forelimb 
misses out of 100 forelimb steps was reported.  
3.5. Assessment of Cognitive Function  
The Morris water maze (MWM) was used to assess the impact of phenoxybenzamine on cognitive 
function (learning and memory) following TBI. The assessment procedure was performed as 
previously published [18]. Pre-acclimation began on day 24 post-TBI. The training phase began on day 
25 post-injury, and the probe trial was conducted on day 30 post-injury. The water temperature was 
maintained at a constant 19 degrees Celsius with the clear plexiglas escape platform 2 cm below the 
water level. All data was recorded and analyzed using Anymaze software connected to a Logitech 
camera. All data sets were analyzed by a blinded researcher. There were no significant differences in 
swim speeds between any of the animals tested. 
3.6. RNA Isolation/Qrt-PCR 
Three biological replicates were used for each experimental group and each replicate was run in 
triplicate. Total RNA was isolated from the rat ipsilateral cortex utilizing Trizol LS (Life technologies 
Carlsbad, CA, USA) according to the manufacturer’s protocol. To remove any contaminating 
chemicals that could affect downstream analysis, RNA was further purified using the RNeasy 
MinElute Cleanup Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. RNA 
was quantified using a Nano Drop spectrophotometer (Cole-Parmer, Vernon Hills, IL, USA. RNA was 
considered acceptable if the 260/280 and 260/230 ratios were 2.0 or greater. A 1 µg aliquot of total 
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RNA was reverse transcribed to cDNA using Qiagen’s RT2 First Strand Kit (Qiagen, Valencia, CA, 
USA). One half of the cDNA reaction was mixed with 675 µL of Qiagen’s 2X RT SYBR Green 
Mastermix and 624 µL H2O. This was then added to a custom array panel (SA Biosciences, Valencia, 
CA, USA) and cycled according to the manufacturer’s suggested qPCR protocol on a iQ5 
thermocycler (Bio-Rad, Hercules, CA, USA). Values were normalized for GAPDH. For data analysis, 
the ΔΔCt method was used with the aid of the manufacturer’s online software suite RT2 Profiler PCR 
Array Data Analysis version 3.5 (SA Biosciences, Valencia, CA, USA). Fold-changes were calculated 
and results compared to normal controls. Please note: (2−ΔΔCt) is the normalized gene expression (2−ΔCt) 
in the test sample divided the normalized gene expression (2−ΔCt) in the Control Sample. Fold-Regulation 
represents fold-change results in a biologically meaningful way. Fold-change values greater than one 
indicate a positive- or an up-regulation, and the fold-regulation is equal to the fold-change. Controls 
for this experiment underwent the trephination surgery but did not receive a TBI. 
3.7. Statistical Analysis  
All data was analyzed using Prizm software (GraphPad, La Jolla, CA, USA). To determine 
Gaussian (normal) distribution a Kolmogorof-Smirnov test was performed on all data sets. Analysis on 
data sets with more than two groups was done using one-way ANOVA with Tukey’s post-hoc to 
determine statistical significance between groups. A p < 0.05 or less was considered significant. 
4. Conclusions  
Clinically, phenoxybenzamine is FDA approved and currently used to treat hypertension and 
sweating associated with pheochromocytoma, a condition in which the adrenal glands secrete high 
levels of noradrenaline and adrenaline. As a therapeutic, the side effects of phenoxybenzamine are 
minimal: stuffy nose, mild drowsiness, blurred vision, and upset stomach. As a treatment for TBI it 
possesses several advantages. It can be delivered intravenously, it efficiently crosses the blood brain 
barrier, it produces mild side effects, and it significantly reduces neurological and cognitive 
dysfunction when delivered 8 h after a severe TBI. Taken together, it is our opinion that 
phenoxybenzamine warrants further investigation as a potential neuroprotective agent for TBI. 
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